Thalidomide-O-C8-NH2 hydrochloride

Background Introduction

Thalidomide-O-C8-NH2 hydrochloride is a versatile E3 ligase ligand-linker conjugate based on the thalidomide pharmacophore. This compound harnesses the ability of thalidomide derivatives to recruit the cereblon (CRBN) E3 ubiquitin ligase, making it an essential building block for PROTAC (Proteolysis Targeting Chimera) and molecular glue development. The introduction of an optimal C8 alkyl chain with a terminal amine provides a functional handle for chemical conjugation, broadening its utility in targeted protein degradation research.

Mechanism

The mechanism of action for Thalidomide-O-C8-NH2 hydrochloride involves its specific binding to the cereblon (CRBN) E3 ubiquitin ligase substrate receptor. In PROTAC design, the thalidomide moiety serves as the E3 ligase recruiting element. The flexible C8 linker, terminating in a primary amine, allows for the facile attachment to a ligand for a target protein. When incorporated into a PROTAC molecule, Thalidomide-O-C8-NH2 hydrochloride facilitates the formation of a ternary complex between the E3 ligase and the protein of interest. This results in ubiquitination and proteasomal degradation of the target protein, promising enhanced selectivity and potency in drug development.

Applications

Thalidomide-O-C8-NH2 hydrochloride is widely utilized in the synthesis of PROTACs and molecular glues aimed at degrading challenging protein targets implicated in cancer, neurodegeneration, and other diseases. Researchers use this ligand-linker conjugate to couple with various protein-targeting warheads, enabling rapid assembly and optimization of heterobifunctional molecules. It is also valuable in structure-activity relationship (SAR) studies, screening for highly efficient degrader molecules, and expanding the chemical toolbox for targeted protein degradation platforms in drug discovery.

• Extended C8 alkyl chain improves linker flexibility and spatial orientation for efficient PROTAC design.
• Amine terminal group enables reliable conjugation with various warheads, ideal for targeted protein degradation via the CRBN pathway.

Thalidomide-O-C8-NH2 hydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by bridging target proteins and E3 ligases. This compound offers an effective strategy for regulating protein levels in cellular environments, enhancing selectivity, and minimizing off-target effects. The following provides a detailed description of this molecule.

Linker: The linker in Thalidomide-O-C8-NH2 hydrochloride is an eight-carbon chain, offering moderate flexibility that balances stability and adaptability. Its non-cleavable nature ensures sustained interaction between the ligand and the target protein, providing prolonged efficacy in degradation processes.

Ligand: The ligand component is derived from thalidomide, a small molecule that binds effectively to the cereblon E3 ligase. Its structural characteristics include a phthalimide moiety, which is crucial for the recruitment of the E3 ligase, facilitating the ubiquitination and subsequent degradation of the target protein.

Reactive Site: The reactive site in this molecule is the terminal amino group, which couples with the target protein ligand. Recommended reaction types include amide bond formation, enabling a stable and covalent linkage that is essential for robust PROTAC development.

Recommended Target Protein Ligand: A compatible warhead for this molecule is a small molecule inhibitor with a carboxyl group, allowing for efficient coupling through amide bond formation. This approach enhances the specificity of the PROTAC, making it suitable for applications in studying protein functions and validating therapeutic targets in preclinical research.